

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number
WO 02/051807 A1

(51) International Patent Classification⁷: **C07D 211/24**,
C07C 255/57, C07D 417/12, 211/22, 211/34, 211/20,
A61K 31/445, 31/44, A61P 25/00, 29/00

SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/SE01/02858

(22) International Filing Date:
20 December 2001 (20.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0004827-2 22 December 2000 (22.12.2000) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SHENVI, Ashokkumar, Bhikkappa** [US/US]; AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS

(57) Abstract: A compound having general formula (I), and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

WO 02/051807 A1

COMPOUNDS

Background

The mammalian neurokinins comprise a class of peptide neurotransmitters which are found in the peripheral and central nervous systems. The three principal neurokinins are Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB).

There are also N-terminally extended forms of at least NKA. At least three receptor types are known for the three principal neurokinins. Based upon their relative selectivities favoring the neurokinin agonists SP, NKA and NKB, the receptors are classified as neurokinin 1 (NK₁), neurokinin 2 (NK₂) and neurokinin 3 (NK₃) receptors, respectively.

It is now recognized that anxiety, stress, and depression are interrelated conditions (File SE *Pharmacol, Biochem & Behavior* 54/1:3-12, 1996). Moreover, these complex emotional states cannot be due simply to defects in a single neurotransmitter although 5-HT has been ascribed a principal role (Graeff et al., *Pharmacol, Biochem & Behavior* 54/1: 129-141, 1996). Substance P (SP) was one of the first neuropeptides to be identified in mammalian brain and it is now accepted that all three tachykinins are found within the CNS (Iversen LL *J Psychopharmacol* 3/1: 1-6, 1989), particularly in the striatonigral neurons, hypothalamus and limbic forebrain (ibid). NK₁ and NK₃ receptors have been identified in the brain as well (Beaujouan et al., *Neurosci.* 18: 857-875, 1986). Controversy has existed regarding the presence of the NK₂ receptor in brain, although recent evidence shows receptor localization in at least the septal region (Steinberg et al., *Eur J Neurosci* 10/7:2337-45 1998).

Pharmacological evidence supporting a role for either NK₁ or NK₂ receptors in anxiety disorders has been accumulating from assorted animal behavioral tests (for examples, see Table 1). Animal models of depression, however, have been used rarely to define the potential utility of NK receptor antagonists. SP stimulates the turnover of other neurotransmitters involved in depression, i.e., 5-HT in the raphe nucleus, an area thought to be linked to depressive phenomena (Forchetti et al., *J. Neurochem.* 38: 1336-1341, 1982). When injected centrally to nuclei responsible for control of emotion and stress, SP evokes a hemodynamic pressor response bridging this peptide to stress induced hypertension (Ku et al., *Peptides*;19/4:677-82, 1998). Moreover, rises in both heart rate and mean arterial blood pressure evoked by physical stress can be blocked in rodents by centrally administered NK₁ receptor antagonists (Culman et al., *J Pharmacol Exp Ther* 280/1:238-46, 1997).

Table 1. Neurokinin receptor antagonist activity in behavioral tests of anxiety/depression.


<u>Author</u>	<u>Cpd (Receptor type)</u>	<u>Behavioral Test</u>	<u>Outcome</u>
Teixeira et al., <i>Eur J Pharmacol</i> 5;311(1):7-14, 1996.	NK ₁ agonists & FK888 (NK ₁) SR48968 (NK ₂)	Elevated plus-maze	agonists - anxiogenic antagonists - anxiolytic
File <i>Pharm Bio B</i> 58(3): 747-752, 1997.	CGP 49823 (NK ₁)	Social interaction	anxiolytic
Vassout et al Neuropeptides 26/S1: 38, 1994.	CGP 49823 (NK ₁)	Social interaction test Elevated plus-maze Forced swim test (depression model)	anxiolytic inactive antidepressant (only at 30mg/kg bid)
Stratton et al., <i>Eur. J. Pharmacol.</i> 250: R11-12, 1993.	GR100679 (NK ₂) SR48968 (NK ₂)	Light-dark box	anxiolytic
Walsh et al., <i>Psychopharmacology</i> 121: 186-191, 1995.	GR159897 (NK ₂) SR48968 (NK ₂)	Light-dark box Marmoset human intruder	anxiolytic anxiolytic

Description

This invention relates to N-substituted amides; to the manufacture of medicaments containing such compounds; as well as to their uses. These compounds antagonize the pharmacological actions of the neurokinin 1 (NK₁) receptor. These compounds are useful whenever such antagonism is desired. Thus, such compounds are of value in the treatment of those diseases in which Substance P is implicated, for example, in the treatment of major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety,


mania or hypomania, aggressive behaviour, obesity, emesis, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, or urticaria.

5 Accordingly, the present invention provides compounds of the general formula



The compounds of the present invention may possess a number of chiral centers, for example at $-\text{CH}(\text{Ph}-\text{X}^1, \text{X}^2)-$. The present invention covers all isomers, diastereoisomers and mixtures thereof that antagonize NK_1 .

10 The preferred configuration at $-\text{CH}(\text{Ph}-\text{X}^1, \text{X}^2)-$ is shown hereinbelow:



X^1 and X^2 are independently hydrogen, methyl or halogen. Preferably, X^1 and X^2 are independently hydrogen or halogen provided that at least one of X^1 or X^2 is halogen. Most favourably, X^1 and X^2 are both chloro. In a preferred aspect $\text{Ph}-\text{X}^1, \text{X}^2$ is 3,4-dichlorophenyl.

15 R^1 is C_{1-4} alkyl, substituted by 1 or 2 substituents selected from $-\text{NR}^a\text{R}^a$, $-\text{NR}^a\text{C}(=\text{O})\text{R}^a$, $-\text{C}(=\text{O})\text{NR}^a\text{R}^a$, $-\text{OR}^a$, $-\text{OC}(=\text{O})\text{R}^a$, $-\text{C}(=\text{O})\text{OR}^a$, $-\text{S}(=\text{O})_n\text{C}_{1-6}$ alkyl, nitro, cyano and C_{1-3} haloalkyl; phenyl substituted by 0, 1, 2 or 3 substituents selected from $-\text{NR}^a\text{R}^a$, $-\text{NR}^a\text{C}(=\text{O})\text{R}^a$, $-\text{C}(=\text{O})\text{NR}^a\text{R}^a$, $-\text{OR}^a$, $-\text{OC}(=\text{O})\text{R}^a$, $-\text{C}(=\text{O})\text{OR}^a$, $-\text{S}(=\text{O})_n\text{C}_{1-6}$ alkyl, nitro, cyano and C_{1-3} haloalkyl; or a 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms
20 each independently selected from O, N and S and additionally having 0 or 1 oxo groups and 0 or 1 fused benzo rings.

R^2 is H, halogen, $-\text{OR}^9$ or C_{1-4} alkyl.


R^3 is H, halogen, $-OR^9$ or $-CN$.

R^4 is H, halogen, $-OR^9$ or C_{1-4} alkyl.

R^5 is H or CH_3 .

R^6 is halogen, $-CH_2CO_2R^a$, $-CH_2C(=O)H$, $-CH_2CH=CH_2$, $-CH_2CH_2OR^a$,

5 $-CH_2CH_2NR^aR^a$ or



R^7 is phenyl substituted by 0, 1, 2 or 3 substituents selected from C_{1-6} alkyl, $-NR^aR^a$, $-NR^aC(=O)R^a$, $-C(=O)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-C(=O)R^a$, $-C(=O)OR^a$, $-S(=O)_nC_{1-6}$ alkyl, nitro, cyano, C_{1-3} haloalkyl, trifluoromethylthio, trifluoromethylsulfinyl, C_{1-6} alkanesulfonamido, succinamido, carbamoyl, C_{1-6} alkylcarbamoyl, di- C_{1-6} alkylcarbamoyl, C_{1-6} alkoxy- C_{1-6} alkylcarbamoyl, ureido, C_{1-6} alkylureido, di(C_{1-6} alkyl)ureido, bromo, fluoro, chloro and dimethylcarbamoylmethylureido; or R^7 is a 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms each independently selected from O, N and S and additionally having 0 or 1 oxo groups substituted by 0 or 1 substituents selected from $-OR^a$, $-OC(=O)R^a$, $-C(=O)OR^a$, $-C(=O)R^a$, $-NR^aR^a$, $-NR^aC(=O)R^a$ and $-C(=O)NR^aR^a$; or R^7 is hydrogen or NR^aR^a .

R^8 is selected from hydrogen, $-OR^a$, $-OC(=O)R^a$, $-C(=O)OR^a$, $-C(=O)R^a$, $-NR^aR^a$, $-NR^aC(=O)R^a$, $-C(=O)NR^aR^a$, C_{1-6} alkyl, carbamoyl, C_{1-6} alkylcarbamoyl, and bis(C_{1-6} alkyl)carbamoyl.

20 R^a is independently at each instance hydrogen or C_{1-6} alkyl.


R^b is C_{1-6} alkyl, phenyl or phenyl C_{1-6} alkyl.

n is 0, 1 or 2.


In one embodiment of the above compounds, R^1 is C_{1-4} alkyl, substituted by 1 or 2 substituents selected from $-C(=O)NR^aR^a$, $-C(=O)OR^a$ and C_{1-3} haloalkyl; phenyl substituted by 0, 1, 2 or 3 substituents selected from $-NR^aR^a$, $-NR^aC(=O)R^a$, $-OR^a$, $-OC(=O)R^a$, nitro, cyano and C_{1-3} haloalkyl; or a 5- or 6-membered ring heterocycle containing 1, 2 or 3 nitrogen atoms.

In another embodiment of the above compounds, R^6 is

- 5 -



In another embodiment of the above compounds, R¹ is C₁₋₄alkyl, substituted by 1 or 2 substituents selected from -C(=O)NR^aR^a, -C(=O)OR^a and C₁₋₃haloalkyl; phenyl substituted by 0, 1, 2 or 3 substituents selected from -NR^aR^a, -NR^aC(=O)R^a, -OR^a, -OC(=O)R^a, nitro, cyano and C₁₋₃haloalkyl; or a 5- or 6-membered ring heterocycle containing 1, 2 or 3 nitrogen atoms; and R⁶ is



In another embodiment of the above compounds, R⁷ is phenyl substituted by 0, 1, 2 or 3 substituents selected from C₁₋₆alkyl, -NR^aR^a, -NR^aC(=O)R^a, -C(=O)NR^aR^a, -OR^a, -OC(=O)R^a, -C(=O)R^a, -C(=O)OR^a, -S(=O)_nC₁₋₆alkyl, nitro, cyano, C₁₋₃haloalkyl, bromo, fluoro and chloro.

In another embodiment of the above compounds, R⁷ is a 5- or 6-membered ring heterocycle containing 1 or 2 heteroatoms each independently selected from O, N and S and additionally having 0 or 1 oxo groups substituted by 0 or 1 -C(=O)NR^aR^a.

In another embodiment of the above compounds, R⁷ is NR^aR^a.

In another embodiment of the above compounds, R⁸ is selected from hydrogen, -NR^aR^a, -NR^aC(=O)R^a and -C(=O)NR^aR^a.


Another aspect of the invention involve a method for manufacturing a medicament comprising an effective amount of an NK1 antagonist according to any of the compounds described above for the treatment of major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, emesis, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, COPD, hypertension, migraine, bladder hypermotility or urticaria.

Another aspect of the invention involves a method of treating major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, emesis, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, COPD, hypertension, migraine, bladder hypermotility, or urticaria comprising administering an effective amount of an NK₁ antagonist according to any of the compounds described above.

Particular compounds of this invention are provided as the Examples hereinbelow.

C_Y-zalkyl, unless otherwise specified, means an alkyl chain containing a minimum Y total carbon atoms and a maximum Z total carbon atoms. These alkyl chains may be branched or unbranched, cyclic, acyclic or a combination of cyclic and acyclic. For example, the following substituents would be included in the general description "C₄₋₇alkyl":

15



C_Y-zhaloalkyl, unless otherwise specified, means an alkyl group, as described above, wherein any number of the hydrogen atoms usually present on the alkyl are replaced with halogen atoms.

Pharmaceutically-acceptable salts may be prepared from the corresponding acid in conventional manner. Non-pharmaceutically-acceptable salts may be useful as intermediates and as such are another aspect of the present invention.

The term "oxo" means a double bonded oxygen (=O).

Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, citrate, cyclohexyl sulfamate, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethyl-sulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as aluminum, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, ornithine, and so forth. Also, basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides like benzyl bromide and others. Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.

The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt and pharmaceutically acceptable carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation or insufflation. For

these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous,
5 intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions
10 referred to herein.

The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.01 to 25 mg/kg body weight (and preferably of 0.1 to 5 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration
15 depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention. For example a tablet or capsule for oral administration may conveniently contain up to 250 mg (and typically 5 to 100 mg) of a compound of the formula (I) or a
20 pharmaceutically acceptable salt thereof. In another example, for administration by inhalation, a compound of the formula (I) or a pharmaceutically acceptable salt thereof may be administered in a daily dosage range of 5 to 100 mg, in a single dose or divided into two to four daily doses. In a further example, for administration by intravenous or intramuscular injection or infusion, a sterile solution or suspension containing up to 10% w/w (and typically
25 5% w/w) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof may be used.

Therefore in a further aspect, the present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof for use in a method of therapeutic treatment of the human or animal body.

30 In yet a further aspect the present invention provides a method of treating a disease condition wherein antagonism of the NK₁ receptor is beneficial which comprises administering to a warm-blooded animal an effective amount of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof. The present invention also provides the use

of a compound of the formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in a disease condition wherein antagonism of the NK₁ receptor is beneficial.

The compounds of the formula (I) and their pharmaceutically acceptable salts may be made by processes as described and exemplified herein and by processes similar thereto and by processes known in the chemical art. If not commercially available, starting materials for these processes may be made by procedures which are selected from the chemical art using techniques which are similar or analogous to the synthesis of known compounds.

It is well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form or by synthesis from optically-active starting materials) and how to determine the NK₁ antagonist properties by the standard tests known in the art and those described hereinafter.

Some individual compounds within the scope of this invention may contain double bonds. Representations of double bonds in this invention are meant to include both the E and the Z isomer of the double bond. Additionally, some species within the scope of this invention may contain one or more asymmetric centers. This invention includes the use of any of the optically pure stereoisomers as well as any combination of stereoisomers.

In general, compounds bearing a 2-substituted naphthamide can exist as a mixture of conformational isomers (atropisomers); this is believed to result from slow rotation about the naphthalene amide and/or aryl bonds ("The Chemistry of Rotational Isomers"; Oki, M.; Springer Verlag, NY; 1993). Where individual atropisomers have been isolatable, distinct chemical and biological properties have been observed. The compounds of this invention comprise both mixtures of, and individual, atropisomers.

The following biological test methods, data and Examples serve to illustrate and further describe the invention.

The utility of a compound of the invention or a pharmaceutically acceptable salt thereof (hereinafter, collectively referred to as a "compound") may be demonstrated by standard tests and clinical studies, including those disclosed in the publications described below.

SP Receptor Binding Assay (Test A)

The ability of a compound of the invention to antagonize the binding of SP at the NK₁ receptor may be demonstrated using an assay using the human NK₁ receptor expressed in Mouse Erythroleukemia (MEL) cells. The human NK₁ receptor was isolated and

characterized as described in: B. Hopkins, et al. "Isolation and characterization of the human lung NK₁ receptor cDNA" Biochem. Biophys. Res. Comm., 1991, 180, 1110-1117; and the NK₁ receptor was expressed in Mouse Erythroleukemia (MEL) cells using a procedure similar to that described in Test B below.

5 **Neurokinin A (NKA) Receptor Binding Assay (Test B)**

The ability of a compound of the invention to antagonize the binding of NKA at the NK₂ receptor may be demonstrated using an assay using the human NK₂ receptor expressed in Mouse Erythroleukemia (MEL) cells, as described in: Aharony, D., et al. "Isolation and Pharmacological Characterization of a Hamster Neurokinin A Receptor cDNA"

10 Molecular Pharmacology, 1994, 45, 9-19.

The selectivity of a compound for binding at the NK₁ and the NK₂ receptors may be shown by determining its binding at other receptors using standard assays, for example, one using a tritiated derivative of NKB in a tissue preparation selective for NK₃ receptors. In general, the compounds of the invention which were tested demonstrated statistically
15 significant binding activity in Test A and Test B with a K_i of 1 mM or much less typically being measured.

Rabbit Pulmonary Artery: NK₁ in vitro functional assay (Test C)

The ability of a compound of the invention to antagonize the action of the agonist Ac-[Arg⁶, Sar⁹, Met(O₂)¹¹] Substance P (6-11), ASMSP, in a pulmonary tissue may be
20 demonstrated as follows.

Male New Zealand white rabbits are euthanized via i.v. injection into the ear vein with 60 mg/kg Nembutal (50 mg/mL). Preceding the Nembutal into the vein is Heparin (1000 units/mL) at 0.0025 mL/kg for anticoagulant purposes. The chest cavity is opened from the top of the rib cage to the sternum and the heart, lungs and part of the trachea are removed.
25 The pulmonary arteries are isolated from the rest of the tissues and cut in half to serve as pairs.

The segments are suspended between stainless steel stirrups, so as not to remove any of the endothelium, and placed in water-jacketed (37.0 °C) tissue baths containing physiological salt solution of the following composition (mM): NaCl, 118.0; KCl, 4.7; CaCl₂,
30 1.8; MgCl₂, 0.54; NaH₂PO₄, 1.0; NaHCO₃, 25.0; glucose, 11.0; indomethacin, 0.005 (to inhibit cyclooxygenase); and *dl*-Propranolol, 0.001(to block β receptors); gassed continuously

with 95% O₂-5% CO₂. Responses are measured on a Grass polygraph via Grass FT-03 transducers.

Initial tension placed on each tissue is 2 grams, which is maintained throughout the 1.0 hour equilibration period. Tissues are washed with the physiological salt solution at 15 minute intervals. At the 30 and 45 minute wash the following treatments are added: 1 x 10⁻⁶ M Thiorphan (to block E.C.3.4.24.11), 3 x 10⁻⁸ M (S)-N-[2-(3,4-dichlorophenyl)-4-[4-(2-oxoperhydropyrimidin-1-yl)piperidino]butyl]-N-methylbenzamide (to block NK₂ receptors), and the given concentration of the compound being tested. At the end of the 1.0 h equilibration, 3 x 10⁻⁶ M Phenylephrine hydrochloride is added for 1.0 h. At the end of 1.0 h, a dose relaxation curve to ASMSP is done. Each tissue is treated as a individual and is considered finished when it fails to relax further for 2 consecutive doses. When a tissue is complete, 1 x 10⁻³ M Papaverine is added for maximum relaxation.

Percent inhibition is determined when a tested compound produces a statistically significant (p < 0.05) reduction of the total relaxation which is calculated using the total relaxation of the Papaverine as 100%. Potencies of the compounds are determined by calculating the apparent dissociation constants (K_B) for each concentration tested using the standard equation:

$$K_B = [\text{antagonist}] / (\text{dose ratio} - 1)$$

where dose ratio = antilog[(agonist -log molar EC₅₀ without compound) - (-log molar EC₅₀ with compound)]. The K_B values may be converted to the negative logarithms and expressed as -log molar K_B (i.e. pK_B). For this evaluation, complete concentration-response curves for agonist obtained in the absence and presence of the compound tested using paired pulmonary artery rings. The potency of the agonist is determined at 50% of its own maximum relaxation in each curve. The EC₅₀ values are converted to negative logarithms and expressed as -log molar EC₅₀.

NK₂ in vitro functional assay (Test D)

The ability of a compound of the invention to antagonize the action of the agonist [β-ala8] NKA (4-10), BANK, in a pulmonary tissue may be demonstrated as follows. Male New Zealand white rabbits are euthanized via i.v. injection into the ear vein with 60 mg/kg Nembutal (50 mg/mL). Preceding the Nembutal into the vein is Heparin (1000 units/mL) at 0.0025 mL/kg for anticoagulant purposes. The chest cavity is opened from the top of the rib cage to the sternum and a small incision is made into the heart so that the left

and right pulmonary arteries can be cannulated with polyethylene tubing (PE260 and PE190 respectively). The pulmonary arteries are isolated from the rest of the tissues, then rubbed over an intimal surface to remove the endothelium, and cut in half to serve as pairs. The segments are suspended between stainless steel stirrups and placed in water-jacketed (37.0 °C) tissue baths containing physiological salt solution of the following composition (mM): NaCl, 118.0; KCl, 4.7; CaCl₂, 1.8; MgCl₂, 0.54; NaH₂PO₄, 1.0; NaHCO₃, 25.0; glucose, 11.0; and indomethacin, 0.005 (to inhibit cyclooxygenase); gassed continuously with 95% O₂-5% CO₂. Responses are measured on a Grass polygraph via Grass FT-03 transducers.

Initial tension placed on each tissue is 2 g, which is maintained throughout the 45 min equilibration period. Tissues are washed with the physiological salt solution at 15 min intervals. After the 45 min equilibration period, 3 x 10⁻² M KCl is given for 60 min to test the viability of the tissues. The tissues are then washed extensively for 30 min. The concentration of the compound being tested is then added for 30 min. At the end of the 30 min, a cumulative dose response curve to BANK is performed. Each tissue is treated as a individual and is considered finished when it fails to contract further for 2 consecutive doses. When a tissue is complete, 3 x 10⁻² M BaCl₂ is added for maximum contraction.

Percent inhibition is determined when a tested compound produces a statistically significant ($p < 0.05$) reduction of the total contraction which is calculated using the total contraction of the BaCl₂ as 100%. Potencies of the compounds are determined by calculating the apparent dissociation constants (K_B) for each concentration tested using the standard equation:

$$K_B = [\text{antagonist}] / (\text{dose ratio} - 1)$$

where dose ratio = $\text{antilog}[(\text{agonist} - \log \text{molar EC}_{50} \text{ without compound}) - (-\log \text{molar EC}_{50} \text{ with compound})]$. The K_B values may be converted to the negative logarithms and expressed as $-\log \text{molar } K_B$ (i.e. pK_B). For this evaluation, complete concentration-response curves for agonist obtained in the absence and presence of the compound tested using paired pulmonary artery rings. The potency of the agonist is determined at 50% of its own maximum relaxation in each curve. The EC_{50} values are converted to negative logarithms and expressed as $-\log \text{molar EC}_{50}$.

30 NK₁ and NK₂ in vivo functional assay (Test E)

The activity of a compound as an antagonist of NK₁ and/or NK₂ receptors also may be demonstrated in vivo in laboratory animals as described in: Buckner et al. "Differential Blockade by Tachykinin NK₁ and NK₂ Receptor Antagonists of Bronchoconstriction Induced

by Direct-Acting Agonists and the Indirect-Acting Mimetics Capsaicin, Serotonin and 2-Methyl-Serotonin in the Anesthetized Guinea Pig." *J. Pharm. Exp. Ther.*, 1993, Vol 267(3), pp.1168-1175. The assay is carried out as follows.

Compounds are tested in anesthetized guinea pigs pretreated with i.v. indomethacin
5 (10 mg/kg, 20 min), propranolol (0.5 mg/kg, 15 min), and thiorphan (10 mg/kg, 10 min).

Antagonists or vehicle are administered i.v. and orally, 30 and 120 min prior to increasing concentrations of agonist, respectively. The agonists used in these studies are ASMSP (Ac-[Arg⁶,Sar⁹,Met(O₂)¹¹]-SP(6-11)) and BANK (β-ala-8 NKA4-10).

Administered i.v., ASMSP is selective for NK₁ receptors, and BANK is selective for
10 NK₂ receptors. Maximum response is defined as zero conductance (G_L, 1/Rp). ED₅₀ values are calculated (the dose of agonist resulting in a reduction of G_L to 50% of baseline), and converted to the negative logarithm (-logED₅₀). The ED₅₀ values, obtained in the presence (P) and absence (A) of antagonist, are used to calculate a Dose Ratio (P/A), an expression of potency. Data are expressed as mean ± SEM and statistical differences were determined using
15 ANOVA/Tukey-Kramer and Student's t-test, with p < 0.05 considered statistically significant.

Compounds of the present invention exhibit marked activity in the foregoing tests and are considered useful for the treatment of those diseases in which the NK₁ and/or NK₂ receptor is implicated, for example, in the treatment of asthma and related conditions.

20

Examples

The invention will now be illustrated by the following non-limiting examples, in which, unless stated otherwise:

- 25 (i) temperatures are given in degrees Celsius (°C); unless otherwise stated, operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25 °C;
- (ii) organic solutions were dried over anhydrous magnesium sulfate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60 °C;
- 30 (iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
- (iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;

- (v) melting points are uncorrected and (dec) indicates decomposition;
- (vi) final products had satisfactory proton nuclear magnetic resonance (NMR) spectra;
- (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using deuterated chloroform (CDCl_3) as solvent; conventional abbreviations for signal shape are used; for AB spectra the directly observed shifts are reported; coupling constants (J) are given in Hz; Ar designates an aromatic proton when such an assignment is made;
- (viii) reduced pressures are given as absolute pressures in pascals (Pa); elevated pressures are given as gauge pressures in bars;
- (ix) solvent ratios are given in volume:volume (v/v) terms; and
- (x) Mass spectra (MS) were run using an automated system with atmospheric pressure chemical ionization (APCI). Generally, only spectra where parent masses are observed are reported. The lowest mass major ion is reported for molecules where isotope splitting results in multiple mass spectral peaks (for example when chlorine is present).

Terms and abbreviations: solvent mixture compositions are given as volume percentages or volume ratios. In cases where the NMR spectra are complex, only diagnostic signals are reported. atm = atmospheric pressure, Boc = t-butoxycarbonyl, Cbz = benzyloxy-carbonyl, DCM = methylene chloride, DIPEA = diisopropylethylamine, DMF = N,N-dimethylformamide, DMSO = dimethyl sulfoxide, Et_2O = diethyl ether, EtOAc = ethyl acetate, equiv. = equivalent(s), h = hour(s), HPLC = high performance liquid chromatography, min = minutes, NMR = nuclear magnetic resonance, psi = pounds per square inch, TFA = trifluoroacetic acid, THF = tetrahydrofuran.

Standard reductive amination refers to the typical procedure in which a solution of an amine (1-1.2 equiv.), an aldehyde (1-1.2 equiv.) and acetic acid (2 equiv.) is stirred in methanol for 5 to 60 min before adding NaBH_3CN (1.7 equiv.). After 1-16 h the reaction is optionally concentrated, dissolved in DCM, and washed with saturated sodium bicarbonate and then purified by chromatography.

Standard Swern oxidation conditions refer to the oxidation of an alcohol to the corresponding aldehyde according to Mancuso, AJ; Huang, SL; Swern, D; J. Org. Chem.; 1978, 2840.

Standard formation of an acid chloride refers to the typical procedure in which a solution of a substituted carboxylic acid in DCM is stirred with 1-1.2 equiv. of oxalyl chloride and a catalytic amount of DMF for 1-12 h, concentrated under reduced pressure, and used without purification.

5 Standard acylation refers to the typical procedure in which an acid chloride (1-1.2 equiv.) is added to a stirred solution of an amine (1-1.2 equiv.) and triethylamine (2 equiv.) in DCM. After 1-16 h the reaction is optionally concentrated, dissolved in DCM, and washed with saturated sodium bicarbonate and then purified by chromatography.

Where noted that a final compound was converted to the citrate salt, the free base was
10 combined with citric acid (1.0 equiv.) in methanol, concentrated under reduced pressure and dried under vacuum (25-70 °C). When indicated that a compound was isolated by filtration from Et₂O, the citrate salt of the compound was stirred in Et₂O for 12-18 h, removed by filtration, washed with Et₂O, and dried under vacuum at 25-70 °C.

Where noted that a final compound was converted to the hydrochloride salt, a solution
15 of HCl in Et₂O was added with stirring to a solution of the purified free base in DCM or methanol. The resulting precipitate was collected by filtration and dried under vacuum.

Each compound bearing a 2-substituted naphthamide existed as a mixture of conformational isomers (atropisomers); this is believed to result from slow rotation about the amide and/or aryl bonds. Such compounds generally showed multiple peaks in HPLC
20 chromatograms and highly complex NMR spectra. In some cases, the individual components of an atropisomeric mixture could be purified by reverse phase HPLC and the properties could be independently evaluated.

Analytical HPLC conditions employed were the following: Hewlett Packard HP1100 system using a Luna C18(2) 4.6x75 mm, 3 micron column (Phenomenex; Torrance, CA) with
25 the following gradient: 0-0.5 min; 20% Solvent B, then ramping linearly to 85% Solvent B at 15 min at a fixed flow rate of 2 mL/min (Solvent A: 0.1% TFA in water; Solvent B: 0.1% TFA in methanol) using UV detection at 255 nm.

Definition of Standard Procedures:

Method A: Standard reductive amination refers to the typical procedure in which a solution
30 of an amine (1-1.2 equivalents), an aldehyde (1-1.2 equivalents) and acetic acid (2 equivalents) are stirred in methanol for 5 to 60 minutes before adding NaBH₃CN (1.7

equivalents). After 1-16 h the reaction is optionally concentrated, dissolved in DCM, and washed with saturated sodium bicarbonate and then purified by chromatography.


Method B: Standard acylation refers to the typical procedure in which an acid chloride (1-1.2 equivalents) is added to a stirred solution of an amine (1-1.2 equivalents) and triethylamine (2 equivalents) in DCM. After 1-16 h the reaction is optionally concentrated, dissolved in DCM, and washed with saturated sodium bicarbonate and then purified by chromatography.

Method C: Swern oxidation refers to the typical procedure in which an alcohol is oxidized to the corresponding aldehyde using a literature procedure.

Method D: Where indicated that a compound was isolated as the citrate salt, the free base was combined with citric acid (1.0 equivalents) in methanol, concentrated under reduced pressure and dried under vacuum (25-70 °C). Where indicated that a compound was isolated as the hydrochloride salt, a solution of HCl in Et₂O was added with stirring to a solution of the purified free base in DCM or methanol. The resulting precipitate was collected by filtration and dried under vacuum.

Method E: Standard trans amidation reaction in which a methanol solution of the starting material containing ammonia in a sealed tube is heated to 100 C for 16 h. Upon concentration under reduced pressure the product is purified by chromatography and converted to citrate salt as described in Method D.


Example 1




Method A

Salt form	citrate
Melting point	150-160 °C
NMR	8.85(m, 1H), 8.2-6.7(m, 12H), 4.8(br., 1H), 4.4(br., 1H), 3.9 (m, 3H), 1.8(br., 5H),
Mass Spec	730 (M+1)

- 17 -




NMR	9.5(three peaks, 1H), 8.3 (m, 1H), 7.8(m, 2H), 7.5(m, 4H), 7.2(m, 1H), 7.0 (m, 1H), 6.9(m, 1H), 6.6(d, d, J ₁ = 2Hz, J ₂ = 4Hz), 4.1(m, 3H).
Mass Spec	507(M- 16)



This olefin was prepared from the corresponding amine using procedures B


NMR	8.3(m, 1H), 7.9-6.6 (m, 7H), 5.2(m, 1H), 4.7(m, 2H), 4.1(m, 3H).
Mass Spec	521(M+1)

5



This amine was prepared from the corresponding aldehyde using method A.


NMR	7.4 (d, J = 4Hz, 1H), 7.25(m, 1H), 7.0 (d, d, J ₁ = 2Hz, J ₂ = 4Hz, 1H), 5.6(m, 1H), 5.0(m, 2H), 3.0(m, 5H), 2.4(m, 2H).
Mass Spec	312 (M+1)



This aldehyde was prepared from the corresponding alcohol using method C.

NMR	9.7 (s, 1H), 7.25(m, 1H), 7.6-7.0 (m, 3H), 5.7(m, 1H), 5.0(m, 2H), 3.6(m, 1H).
Mass Spec	229 (M+1)


5



This alcohol was prepared from the corresponding ester using standard lithiumaluminumhydride conditions.

NMR	7.4 (d, J=4Hz, 1H), 7.35(d, J=1Hz, 1H), 7.05(d,d, J1=1Hz, J2=4Hz, 1H), 5.6(m, 1H), 5.0(m, 2H), 3.8(m, 2H), 2.8(m, 1H), 2.4(m, 2H).
-----	--


10 Example 2




Method A

Salt form	citrate salt
-----------	--------------

Melting point	185-190 °C
NMR	8.7(m, 1H), 8.3-6.8(m, 12H), 4.0 (m, 3H), 1.6(br., 4H).
Mass Spec	705 (M+1)




NMR	9.6(three peaks, 1H), 8.3(M, 1H), 8.0-6.6(m, 7H), 4.2 (m, 3H), 2.6(M, 1H).
Mass Spec	498 (M +1)




5 Method B

NMR	8.3(three peaks, 1H), 8.0-6.2(m, 9H), 4.1 (m, 3H), 2.0(M, 1H).
Mass Spec	496 (M+1)




Method A

NMR	7.4(d, 4Hz, 1H), 7.3(d, J=1Hz, 1H), 7.0(d,d,J1=1Hz, J2=4Hz, 1), 6.8(br., 1H)5.6(m, 1H), 5.0(m, 2H), 3.2(d, J=1Hz, 2H), 2.8(m, 3H), 2.4(m, 2H).
-----	--


Example 3**Method A**

Salt form	citrate
NMR	8.7 (m, 1H), 8.3-6.8(m, 10H), 4.0(two peaks, 3H), 3.8 (s, 3H), 1.7(br., 4H).
Mass Spec	735 (M+1)


5

Example 4**Method A**

Salt form	citrate salt
Melting point	175-180 °C
NMR	8.6 (m, 1H), 8.2-6.8 (m, 7H), 4.0(two peaks, 3H), 1.8(br., 4H).
Mass Spec	721 (M+1)

Example 5**Method A**


Salt form	citrate salt
Melting point	130-135 °C
NMR	8.3(m, 1H), 8.0-6.6(m, 11H), 4.1(three peaks, 3H), 3.8(two peaks, 3H), 3.6(s, 3H), 1.8(br., 2H).
Mass Spec	720 (M+1)




5

Method A

NMR	9.6(three peaks, 1H), 8.3(m, 1H), 8.0-6.6(m, 7H), 4.1(s, 3H), 3.8(m, 3H), 2.6(m, 2H).
-----	---




NMR	8.3(m,1H), 8.0-6.6(m, 7H), 4.1(m, 3H), 3.8(m, 3H), 2.6(m, 2H).
Mass Spec	515 (M+1)




Method A

Mass Spec	322 (M+1)
-----------	-----------


5 **Example 6**

Method A

Salt form	citrate
Melting point	120-130 °C
NMR	8.3 (m, 1H), 7.9-6.6 (m, 10H), 4.0(m, 3H), 3.8(m, 3H), 3.6(m, 3H), 1.8(br., 2H).
Mass Spec	750 (M+1)


Example 7**Method E**

Salt form	citrate
Melting point	120-125 °C
NMR	8.3 (m, 1H), 7.9-6.4 (m, 10H), 4.0(m, 3H), 3.8(m, 3H), 3.6(m, 3H), 1.8(br., 2H).
Mass Spec	735 (M+1)


5 Example 8

Hydrolysis with 1N NaOH in methanol and purification by HPLC.

Salt form	citrate
Melting point	128-165 °C
NMR	8.2(s, 1H), 8.1 (d, J= 3Hz, 1H), 7.9-6.6 (m, 12H), 4.2(m, 3H), 3.6(m, 3H), 1.8(br., 4H).
Mass Spec	735 (M+1)


Example 9**Method E**

Salt form	citrate
Melting point	155-166 °C
NMR	8.6(m, 1H), 8.2-6.4 (m, 12H), 3.6(m, 3H), 1.8(br., 8H).
Mass Spec	675 (M+1)

5 Example 10**Method A.**


NMR	8.2(m, 1H), 8.0-6.6 (m, 12H), 2.6(m, 6H), 1.8(br., 8H).
Mass Spec	690 (M+1)

- 25 -



Method C.


NMR	9.7 (two peaks, 1H), 8.2(m, 1H), 8.0-6.4 (m, 8H), 3.8(m, 2H), 2.6(br., 2H).
Mass Spec	483 (M+1)



5


Method C and then B

NMR	8.2(m, 1H), 8.0-6.6 (m, 8H), 3.8(m, 2H), 3.7-3.4(m, 6H, 3.2(br., 2H).
Mass Spec	485 (M+1)

Example 11

Method A, E.


Salt form	citrate
Melting point	145-162 °C
NMR	8.0-6.4(m, 14H), 3.5(m, 3H), 1.8(br., 8H).
Mass Spec	650 (M+1)

5 Example 12

Method A.


Salt form	citrate
-----------	---------

Melting point	130-162 °C
NMR	8.6 (m, 1H), 8.2-6.6(m, 7H), 3.9(m, 3H), 3.8(m, 3H), 1.6(m, 4H).
Mass Spec	736 (M+1)

Example 13


5 Method A.

Salt form	citrate
Melting point	120-165 °C
NMR	8.6 (m, 1H), 8.1-6.6(m, 12H), 3.9(m, 3H), 3.8(m, 3H), 1.8(m, 4H).
Mass Spec	715 (M+1)

Example 14


Method A.

Salt form	citrate
Melting point	135-155 °C
NMR	8.6 (m, 1H), 8.1-6.6(m, 11H), 3.9(s, 3H), 3.8(m, 3H), 1.8(m, 4H).
Mass Spec	705 (M+1)

Example 15


Method A.

NMR	8.2 (m, 1H), 7.9-6.5(m, 11H), 3.8(s, 3H), 2.6(m, 3H), 1.8(m, 4H).
Mass Spec	720 (M+1)

5 **Example 16**


Method similar to method E was used except that methylamine was used instead of ammonia.

Salt form	citrate
Melting point	115-140 °C
NMR	8.7 (m, 1H), 8.2-6.7(m, 10H), 3.95(m, 3H), 3.8 (m, 3H), 1.8(m, 4H).
Mass Spec	749 (M+1)

Example 17


Method A, E.

Salt form	citrate
Melting point	130-160 °C
NMR	8.6 (m, 1H), 8.2-6.7(m, 7H), 3.95(m, 3H), 3.5 (m, 3H), 13(m, 10H).
Mass Spec	693 (M+1)

5 **Example 18**


Method A, E.

Salt form	citrate
Melting point	125-165 °C
NMR	8.6 (m, 1H), 8.2-6.7(m, 7H), 3.95(m, 3H), 3.5 (m, 3H), 1.3(m, 10H).
Mass Spec	665 (M+1)

Example 19


- 5 A procedure similar to Method E was used except that instead of ammonia hydrazine hydrate was used.

Salt form	citrate
Melting point	135-165 °C
NMR	9.2(m 1H), 8.6 (m, 1H), 8.2-6.7(m, 10H), 3.95(m, 3H), 3.8 (m, 3H), 1.6(m, 4H).
Mass Spec	750 (M+1)

Example 20


Method A, E

Salt form	citrate
Melting point	135-165 °C
NMR	8.7 (m, 1H), 8.2-6.7(m, 10H), 3.95(m, 3H), 1.7(m, 4H).
Mass Spec	723 (M+1)

Example 21


Method A, E.

Salt form	citrate
Melting point	125-140 °C
NMR	8.7 (m, 2H), 8.0 (d, J=4Hz, 1H), 7.6-7.1(m, 10 H), 3.95(s, 3H), 1.8(m, 6H).
Mass Spec	723 (M+1)

Example 22


Method A, E.

Salt form	citrate
Melting point	140-150 °C
NMR	8.7 (m, 2H), 8.1 (d, J=4Hz, 1H), 7.8-7.0(m, 8 H), 3.8-3.2(m, 10H), 1.4(m, 4H).
Mass Spec	663 (M+1)

Example 23


Method A, E.

Salt form	citrate
Melting point	135-140 °C
NMR	8.6 (m, 2H), 8.4-6.4(m, 9 H), 2.0-1.4(m, 10H).
Mass Spec	620 (M+1)

Example 24


Method A, E.

Salt form	citrate
Melting point	140-165 °C
NMR	8.6-6.4(m, 12 H), 3.6 (m, 3H), 1.8-1.6(m, 4H).
Mass Spec	693 (M+1)

Example 25


Method A, E.

Salt form	citrate
Melting point	165-170 °C
NMR	8.6-6.2(m, 9H), 1.8-1.4(m, 8H)
Mass Spec	635 (M+1)

Example 26


Method A, E.

Salt form	citrate
Melting point	160-205 °C
NMR	8.6-6.5 (m, 9H), 1.7(m, 4H).
Mass Spec	580 (M+1)

Example 27


Method A, E.

Salt form	citrate
Melting point	140-185 °C
NMR	8.6 (m, 1H), 8.1 (m, 1H), 7.8-6.5(m, 9 H), 1.1(m, 3H).
Mass Spec	623 (M+1)

Example 28


Method A, E.

Salt form	citrate
Melting point	125-155 °C
NMR	8.6 (m, 1H), 8.1 (m, 1H), 7.8-6.5(m, 9 H), 2.2(two peaks, 6H).
Mass Spec	623 (M+1)

5 **Example 29**


Method A.

Salt form	citrate
Melting point	150-160 °C
NMR	8.7 (m, 1H), 8.0 (m, 1H), 7.8-6.2(m, 7 H), 1.8(m, 6H).
Mass Spec	680 (M+1)

Example 30


Method A, E.

Salt form	citrate
Melting point	220-225 °C
NMR	9.4 (m, 1H), 8.6-6.4(m, 13 H), 1.8(m, 6H).
Mass Spec	629 (M+1)

Example 31


Method A, E.

Salt form	citrate
Melting point	170-175 °C
NMR	8.6 (m, 1H), 8.1 (m, 1H), 7.8-6.5(m, 9 H), 1.6(m, 2H).
Mass Spec	539 (M+1)

Example 32


Method A, E.

Salt form	citrate
Melting point	170-175 °C
NMR	8.6 (m, 1H), 8.1 (m, 1H), 7.8-6.4(m, 9 H), 1.6(m, 6H).
Mass Spec	537 (M+1)

Example 33


Method A, E.

Salt form	citrate
Melting point	170-175 °C
NMR	8.6 (m, 1H), 8.05 (m, 1H), 7.8-6.5(m, 8H), 1.6(m, 8H).
Mass Spec	634 (M+1)

5 **Example 34**


Method B, E.

Melting point	77-85 °C
NMR	8.3-6.3(m, 11H), 1.8 (m, 2H), 1.4(m, 1H).
Mass Spec	445 (M+1)

Example 35


Method B, E.

Melting point	105-110 °C
NMR	8.5(m, 1H), 8.1-6.4 (m, 8H), 1.8 (m, 1H), 1.4(m, 1H).
Mass Spec	471 (M+1)

5 **Example 36**

Method B, E.

Melting point	100-110 °C
NMR	8.3 (m, 1H), 7.8-6.2(m, 7H), 3.4 (m, 6H), 1.6(m, 2H).
Mass Spec	500 (M+1)

Example 37

N-[2-(3,4-Dichlorophenyl)-4-[4-[4-methoxy-(S)-2-methylsulfinylphenyl]-1-piperidinyl]-butyl]-N-[(2-carboxamide)ethyl]-3-cyano-1-naphthamide citrate.

N-[2-(3,4-Dichlorophenyl)-4-[4-[4-methoxy-(S)-2-methylsulfinylphenyl]-1-piperidinyl]butyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide was dissolved in 12 mL MeOH (2.0 M in NH₃) and heated to 70 °C in a sealed tube for 20 h. Mixture was cooled, MeOH was evaporated, product was purified by chromatography (100:1⇒20:1, DCM:MeOH w/0.5% conc. NH₃ (aq)) and converted to the citrate salt; MS: m/z 719 (M+); ¹H NMR (DMSO-d₆) δ 8.64 (s), 8.61 (s), 8.19-8.03 (m), 7.88-6.75 (m), 6.54 (s), 6.32 (d), 4.60 (m), 3.82 (s), 3.81 (s), 3.95-1.50.

10 Intermediates were prepared as follows:

4-[2-(3,4-Dichlorophenyl)]-pentenal.

4-[2-(3,4-Dichlorophenyl)]-pentenol (10.60 g) was reacted with oxalyl chloride/DMSO under standard swern oxidizing conditions in DCM (750 mL) to afford 4-[2-(3,4-dichlorophenyl)]-pentenal (9.76 g crude) as a liquid after aqueous extraction from DCM; ¹H NMR (CDCl₃) δ 9.67 (m), 7.46 (d), 7.30 (d), 7.03 (dd), 5.75-5.55 (m), 5.20-4.90 (m), 3.60 (t), 2.83 (dt), 2.47 (dt).

[2-(3,4-Dichlorophenyl)]-N-[(2-carboxyethyl)ethyl]-4-pentenamine.

β-Alanine ethyl ester hydrochloride (1.10 g) was stirred with 30 mL MeOH and 1.1 mL Et₃N until all had dissolved. To this was added (1.59 g) 4-[2-(3,4-dichlorophenyl)]-pentenal followed by 1.1 mL HOAc. Mixture was stirred for 1.5 h, 0.75 g of NaCNBH₃ was added, and mixture was stirred for 18 h. At this point 100 mL of 20% K₂CO₃ (aq) was added, MeOH was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na₂SO₄, filtered, and concentrated to give an oil (2.09 g); MS: m/z 330 (M+); ¹H NMR (CDCl₃) δ 7.38 (d), 7.28 (d), 7.03 (dd), 5.72-5.50 (m), 5.20-4.78 (m), 4.10 (q), 3.09 (q), 2.95-2.70 (m), 2.60-2.30 (m), 1.36 (t), 1.21 (t).

N-[2-(3,4-Dichlorophenyl)-4-pentenyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide.


1-Naphthoyl chloride (0.97 g) was combined with [2-(3,4-dichlorophenyl)]-N-[(2-carboxyethyl)ethyl]-4-pentenamine (1.49 g) and triethyl amine under standard acylation conditions to afford N-[2-(3,4-dichlorophenyl)-4-pentenyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide (0.56 g) as a solid after purification by chromatography (5:4:1 Hexane:DCM:EtOAc); MS: m/z 509 (M+); ¹H NMR (CDCl₃) δ 8.25-8.10 (m), 7.95-7.05 (m),

6.98-6.80 (m), 6.78-6.62 (m), 6.60-6.41 (m), 5.77-5.58 (m), 5.35-4.72 (m), 4.30-1.90 (m), 1.40-1.15 (m).

N-[2-(3,4-Dichlorophenyl)-4-oxobutyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide.

- 5 To a stirred slurry of N-[2-(3,4-dichlorophenyl)-4-pentenyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide (0.56 g) and NaIO₄ (0.82 g) in 60 mL 1:1 THF:H₂O was slowly added 0.55 mL OsO₄ solution (4% w/w in H₂O). Mixture was stirred for 18 h, 10 mL sat'd Na₂S₂O₃ (aq) was added, THF was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na₂SO₄, filtered, and concentrated.
- 10 This gave 0.26 g of N-[2-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide after purification by chromatography (5:4:1 Hexane:DCM:EtOAc); MS: m/z 511 (M⁺); ¹H NMR (CDCl₃) δ 9.79 (s), 9.56 (s), 9.55 (s), 8.26-8.19 (m), 8.00-7.82 (m), 7.79-7.20 (m), 7.00-6.90 (m), 6.81-6.72 (m), 6.68-6.55 (m), 4.45 (t), 4.30-2.78 (m), 2.60-2.25 (m), 1.40-1.12 (m).
- 15 **N-[2-(3,4-Dichlorophenyl)-4-[4-[4-methoxy-(S)-2-methylsulfinylphenyl]-1-piperidinyl]-butyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide.**
Using standard reductive amination conditions N-[2-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(2-carboxyethyl)ethyl]-3-cyano-1-naphthamide (0.256 g) was reacted with 4-(4-methoxy-2-(S)-methylsulfinylphenyl)piperidine (0.131 g) (synthesis described in a previous filing) to afford
- 20 0.297 g of product after purification by chromatography (100:1⇒20:1, DCM:MeOH w/0.5% conc. NH₃ (aq)); MS: m/z 748 (M⁺); ¹H NMR (CDCl₃) δ 8.26-8.20 (m), 7.98-7.20 (m), 7.03-6.53 (m), 4.55 (t), 4.11-2.20 (m), 3.87 (s), 2.68 (s), 2.65 (s), 2.10-1.50 (m), 1.33 (t), 1.20 (t).

Example 38



- 25 **N-[2-(3,4-Dichlorophenyl)-4-[4-[4-methoxy-(S)-2-methylsulfinylphenyl]-1-piperidinyl]-butyl]-N-[(1(R)-carboxamide)ethyl]-3-cyano-1-naphthamide citrate.**

N-[2-(3,4-Dichlorophenyl)-4-[4-[4-methoxy-(S)-2-methylsulfinylphenyl]-1-piperidinyl]butyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide was dissolved in 12 mL MeOH (2.0 M in NH₃) and heated to 70 °C in a sealed tube for 20 h. Mixture was cooled, MeOH was evaporated, product was purified by chromatography (100:1⇒20:1, DCM:MeOH w/0.5% conc. NH₃ (aq)) and converted to the citrate salt; MS: m/z 719 (M+); ¹H NMR (DMSO-d₆) δ 8.67 (s), 8.62 (s), 8.30-7.98 (m), 7.90-6.61 (m), 3.82 (s), 4.50-1.20 (m), 0.73 (d).

Intermediates were prepared as follows:

[2-(3,4-Dichlorophenyl)]-N-[(1-(R)-carboxymethyl)ethyl]-4-pentenamine.

D-Alanine methyl ester hydrochloride (0.73 g) was stirred with 30 mL MeOH and 0.75 mL Et₃N until all had dissolved. To this was added (1.15 g) 4-[2-(3,4-dichlorophenyl)]-pentenal followed by 1.45 mL HOAc. Mixture was stirred for 1.5 h, 0.50 g of NaCNBH₃ was added, and mixture was stirred for 18 h. At this point 50 mL of 20% K₂CO₃ (aq) was added, MeOH was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na₂SO₄, filtered, and concentrated to give an oil (1.53 g); MS: m/z 316 (M+).

N-[2-(3,4-Dichlorophenyl)-4-pentenyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide.

1-Naphthoyl chloride (1.07 g) was combined with [2-(3,4-dichlorophenyl)]-N-[(1-(R)-carboxymethyl)ethyl]-4-pentenamine (1.53 g) and triethyl amine under standard acylation conditions to afford N-[2-(3,4-dichlorophenyl)-4-pentenyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide (1.05 g) as a solid after purification by chromatography (5:4:1 Hexane:DCM:EtOAc); MS: m/z 495 (M+); ¹H NMR (CDCl₃) δ 8.37-8.11 (m), 7.99-6.40 (m), 5.85-5.55 (m), 5.54-5.21 (m), 5.20-4.69 (m), 4.38-2.41 (m), 2.25-1.81 (m), 1.79-0.75 (m).

N-[2-(3,4-Dichlorophenyl)-4-oxobutyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide.

To a stirred slurry of N-[2-(3,4-dichlorophenyl)-4-pentenyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide (1.05 g) and NaIO₄ (1.01 g) in 60 mL 1:1 THF:H₂O was slowly added 0.64 mL OsO₄ solution (4% w/w in H₂O). Mixture was stirred for 18 h, 10 mL sat'd Na₂S₂O₃ (aq) was added, THF was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na₂SO₄, filtered, and concentrated.


This gave 0.64 g of N-[2-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide after purification by chromatography (5:4:1 Hexane:DCM:EtOAc);

MS: m/z 497 (M⁺); ¹H NMR (CDCl₃) δ 9.77 (s), 9.63 (s), 9.59 (s), 9.51 (s), 8.19-8.09 (m), 8.03-6.38 (m), 4.58-2.35 (m), 1.82 (q), 1.71 (d), 1.50 (d), 1.44 (d), 1.15 (d), 1.01 (d).

N-[2-(3,4-Dichlorophenyl)-4-[4-[4-methoxy-(S)-2-methylsulfinylphenyl]-1-piperidinyl]-butyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide.

- 5 Using standard reductive amination conditions N-[2-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(1-(R)-carboxymethyl)ethyl]-3-cyano-1-naphthamide (0.644 g) was reacted with 4-(4-methoxy-2-(S)-methylsulfinylphenyl)piperidine (0.333 g) (synthesis described in a previous filing) to afford 0.621 g of product after purification by chromatography (100:1⇒20:1, DCM:MeOH w/0.5% conc. NH₃ (aq)); MS: m/z 734 (M⁺); ¹H NMR (CDCl₃) δ 8.30-8.10 (m), 7.98-7.15 (m), 7.05-6.70 (m), 6.55-6.40 (m), 4.55-2.45 (m), 3.92 (s), 3.87 (s), 2.68 (s), 2.66 (s), 2.35-1.30 (m), 0.83 (dd).
- 10


Example 39



- N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]butyl]-N-[(3-pyridyl)methyl]-3-cyano-2-ethyl-1-naphthamide citrate.**
- 15 Using standard reductive amination conditions 2-(S)-(3,4-dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]butanamine (0.244 g) (synthesis described in a previous filing) was reacted with 3-pyridine carboxaldehyde (0.055 g) to afford 0.267 g of N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]]-N-[(3-pyridyl)methyl]butanamine which was used in the next step without purification; LC/MS
- 20 indicated a single component: m/z 560 (M⁺). 3-Cyano-2-ethyl-1-naphthoyl chloride (0.129 g) (synthesis described in a previous filing) was combined with N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]]-N-[(3-pyridyl)methyl]butanamine (0.267 g) and triethyl amine under standard acylation conditions to afford 0.077 g of product
- 25 after purification by chromatography and conversion to the citrate salt; MS: m/z 767 (M⁺); ¹H


NMR (DMSO- d_6) δ 8.85-8.35 (m), 8.20-6.50 (m), 3.82 (s), 4.40-2.30 (m), 2.05-1.50 (m), 1.35-0.88 (m).

Example 40




5 N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]butyl]-N-[2-hydroxyphenylmethyl]-3-cyano-2-ethyl-1-naphthamide citrate.

Using standard reductive amination conditions 2-(S)-(3,4-Dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]butanamine (0.244 g) (synthesis described in a previous filing) was reacted with salicylaldehyde (0.062 g) to afford 0.299 g of N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]]-N-[2-hydroxyphenylmethyl]butanamine which was used in the next step without purification; LC/MS indicated the major component with: m/z 575 (M^+). 3-Cyano-2-ethyl-1-naphthoyl chloride (0.129 g) (synthesis described in a previous filing) was combined with N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]]-N-[2-hydroxyphenylmethyl]butanamine (0.299 g) and triethyl amine under standard acylation conditions. Crude product after work-up was a mixture of O and N acylated material which was dissolved in 10 mL 1:1 THF:H₂O, mixed with 0.05 g LiOH, and stirred for 18 h. Reaction was quenched with 1 mL 1N HCl followed by 20 mL sat'd NaHCO₃. Result was extracted with DCM, extracts were dried over Na₂SO₄, filtered, and concentrated to afford 0.081 g of product after purification by chromatography and conversion to the citrate salt; MS: m/z 782 (M^+); ¹H NMR (DMSO- d_6) δ 9.92-9.85 (m), 9.55-9.45 (m), 8.63-8.52 (m), 8.22-7.90 (m), 7.85-6.80 (m), 6.78-6.57 (m), 5.11 (d), 4.98 (d), 4.76 (t), 4.55 (t), 4.28 (t), 4.13 (d), 4.03 (d), 3.85 (s), 3.82 (s), 3.65-1.42 (m), 1.41-0.78 (m).

Example 41

N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]butyl]-N-[(2-imidazolyl)methyl]-3-cyano-2-ethyl-1-naphthamide citrate.


- 5 Using standard reductive amination conditions 2-(S)-(3,4-Dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]butanamine (0.244 g) (synthesis described in a previous filing) was reacted with 2-imidazole carboxaldehyde (0.051 g) to afford 0.286 g of N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]]-N-[(2-imidazolyl)methyl]butanamine which was used in the next step without purification;
- 10 LC/MS indicated a major component: m/z 549 (M^+). 3-Cyano-2-ethyl-1-naphthoyl chloride (0.129 g) (synthesis described in a previous filing) was combined with N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(4-methoxy-(S)-2-methylsulfinylphenyl)-1-piperidinyl]]-N-[(3-pyridyl)methyl]butanamine (0.286 g) and triethyl amine under standard acylation conditions to afford 0.108 g of product after purification by chromatography and conversion to the citrate
- 15 salt; MS: m/z 756 (M^+); 1H NMR ($DMSO-d_6$) δ 11.18 (br m), 8.90 (s), 8.64 (s), 8.60 (s), 8.25-8.00 (m), 7.97 (d), 7.85-6.90 (m), 6.73 (d), 6.64 (s), 6.44 (s), 6.38 (d), 4.99 (d), 4.90 (d), 4.69 (d), 4.62 (d), 3.82 (s), 3.81 (s), 4.18-1.40 (m), 1.30-0.89 (m).

Example 42

N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide citrate.

Using standard reductive amination conditions N-[2-(S)-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide (0.478 g) (synthesis described elsewhere in this patent) was reacted with 4-(5-bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)piperidine (0.322 g) to afford 0.780 g of N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(5-bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide after purification by chromatography (50:1⇒20:1, DCM:MeOH w/0.5% conc. NH₃ (aq)); MS: m/z 788 (M⁺); ¹H NMR (CDCl₃) δ 8.32-8.14 (m), 8.07-6.60 (m), 4.73 (d), 4.60-4.20 (m), 4.09-2.61 (m), 2.82 (s), 2.81 (s), 2.40-2.21 (m), 2.15-1.30 (m). N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide citrate; MS: m/z 788 (M⁺); ¹H NMR (DMSO-d₆) δ 8.86-8.59 (m), 8.22 (d), 8.15 (d), 8.09 (d), 7.90-7.35 (m), 7.28 (d), 7.17 (d), 7.04 (d), 6.95 (d), 6.54 (d), 6.46 (s), 4.61 (d), 4.50-1.50 (m), 3.80 (s), 3.77 (s), 2.81 (s).

15 **Example 43**



N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl-N-[(carboxamide)methyl]-3-cyano-1-naphthamide citrate.

N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide (0.780 g) was dissolved in 12 mL MeOH (2.0 M in NH₃) and heated to 70 °C in a sealed tube for 20 h. Mixture was cooled, MeOH was evaporated, product was purified by chromatography (100:1⇒20:1, DCM:MeOH w/0.5% conc. NH₃ (aq)) and converted to the citrate salt (0.200 g); MS: m/z 773 (M⁺); ¹H NMR (DMSO-d₆) δ 8.70-8.57 (m), 8.43 (d), 8.19-7.99 (m), 7.94 (s), 7.85-6.91 (m), 6.55 (s), 6.47 (d), 4.62-1.40 (m), 2.81 (s), 2.80 (s).

The intermediates were prepared as follows:

4-Hydroxy-4-(4-fluoro-2-methylthiophenyl)-N-Cbz-piperidine and 4-Hydroxy-4-(5-bromo-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine.

Cerium (III) chloride heptahydrate (246.8 g) was heated under high vacuum at 100 °C for 2 days then at 140 °C for two days. This material was transferred to a dry flask equipped with mechanical stirrer, suspended in 1200 mL anhydrous THF, and stirred while cooling to -78 °C. A solution of 2-bromo-5-fluoro-(thiomethyl)benzene (130.2 g) in 1200 mL anhydrous THF was cooled to -78 °C and treated dropwise with n-butyllithium (236.0 mL of a 2.5 M solution in hexane) over 1 hour. The temperature of the reaction flask was kept below -70 °C during the addition. This mixture was stirred at -78 °C for 1.5 hours and transferred via wide bore insulated cannula into the flask containing the stirred suspension of CeCl₃ at -78 °C. The resulting yellow suspension was stirred for 1 h at -78 °C and then a solution of 1-benzyloxycarbonyl-4-piperidone (137.4g in 200 mL anhydrous THF) was added via cannula over 30 minutes. When the addition was complete the reaction mixture was warmed to room temperature and stirred overnight (18 h). At the end of this period the reaction mixture was quenched with 800 mL saturated NH₄Cl (4 scoops of celite was added) and stirred for 30 minutes. The organic layer was decanted, concentrated under reduced pressure, and set aside. The remaining grayish suspension was filtered and cake was washed with EtOAc (4 x 75 mL). The EtOAc washings and the THF concentrate were combined, dried over MgSO₄, filtered, and concentrated under reduced pressure to give a viscous oil which was purified by chromatography on silica (2 kg) (9:1⇒8:2⇒7:3⇒1:1, EtOAc:hexane) to give 96.00 g of pure 4-hydroxy-4-(4-fluoro-2-methylthiophenyl)-N-Cbz-piperidine; MS m/z 358 (M-H₂O). ¹H NMR (CDCl₃) δ 7.45-7.25 (m), 7.08 (dd), 6.95-6.80 (m), 5.15 (s), 4.30-4.00 (m), 3.82 (s), 3.45-3.20 (m), 2.52 (s), 2.25-1.95 (m). As a side product 4-hydroxy-4-(5-bromo-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine was also isolated; MS m/z 436 (M-H₂O); ¹H NMR (CDCl₃) δ 7.65 (d), 7.41-7.29 (m), 6.80 (d), 5.15 (s), 4.30-4.00 (m), 3.47-3.20 (m), 2.45 (s), 2.25-1.90 (m), 1.74 (d).

4-(5-Bromo-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine.

To an ice-cooled, rapidly stirred slurry of 4-hydroxy-4-(5-bromo-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine (7.82 g) in triethylsilane (19.7 g) was slowly added trifluoroacetic acid (18.6 g). When addition was complete the mixture was warmed to room temperature and stirred overnight (18 h). At the end of this period the mixture was poured into 100 mL saturated NaHCO₃ and extracted with DCM. Extracts were combined, dried over

Na_2SO_4 , filtered, and concentrated under reduced pressure to give an oil. The product was purified by chromatography on silica (7:3, hexane:EtOAc) to give 5.18 g of an oil; MS m/z 438 (M^+); ^1H NMR (CDCl_3) δ 7.45-7.30 (m), 7.25 (d), 6.80 (d), 5.15 (s), 4.50-4.20 (m), 3.11-2.80 (m), 1.90-1.48 (m).


5 **4-(5-Bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)-N-Cbz-piperidine.**

To a stirred solution of NaIO_4 (10.93 g) dissolved in 100 mL H_2O was added 4-(5-bromo-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine (4.25 g) dissolved in 100 mL THF. Mixture was stirred at room temperature for 18 h, 50 mL sat'd NaHCO_3 was added, and THF was evaporated. Result was extracted with DCM (3x75 mL), extracts were combined, dried over
10 Na_2SO_4 , and evaporated to give 2.51 g of product after chromatography (1:1 hexane:EtOAc); MS m/z 454 (M^+); ^1H NMR (CDCl_3) δ 7.65 (d), 7.45-7.25 (m), 5.16 (s), 4.53-4.25 (m), 3.07 (tt), 3.00-2.75 (m), 2.82 (s), 1.85 (d), 1.75-1.56 (m).

4-(5-Bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)piperidine.

A solution of TFA (10 mL) and 2.344 g 4-(5-bromo-2-fluoro-4-(R,S)-methylsulfinylphenyl)-
15 N-Cbz-piperidine was heated to 80 °C for 2 h. TFA was evaporated, residue was mixed with 30 mL 20% KOH (aq), and extracted with CHCl_3 . Extracts were combined, dried over Na_2SO_4 , and evaporated. Residue was purified by chromatography (50:1 \Rightarrow 10:1, DCM:MeOH w/0.5% conc. NH_3 (aq)) to give 0.425 g
product; MS m/z 320 (M^+); ^1H NMR (CDCl_3) δ 7.63 (d), 7.43 (d), 3.21 (dm), 3.01 (tt), 2.82
20 (s), 2.78 (tm), 1.83 (dm), 1.75-1.57 (m).


Example 44



**N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-carboxamide-2-fluoro-4-(R,S)-
methylsulfinylphenyl)-1-piperidinyl]butyl-N-[(carboxymethyl)methyl]-3-cyano-1-
25 naphthamide citrate.**

Using standard reductive amination conditions N-[2-(S)-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide (0.343 g) (synthesis described elsewhere in this patent) was reacted with 4-(5-carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)piperidine (0.197 g) to afford 0.351 g of N-[2-(S)-(3,4-dichlorophenyl)-4-[4-(5-carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl]-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide after purification by chromatography (50:1⇒20:1, DCM:MeOH w/0.5% conc. NH_3 (aq)); MS: m/z 751 (M⁺); ¹H NMR (CDCl_3) δ 8.38-6.55 (m), 5.57 (br s), 4.94 (t), 4.59 (d), 4.05-1.15 (m). N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl]-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide citrate; MS: m/z 751 (M⁺); ¹H NMR ($\text{DMSO}-d_6$) δ 8.87-8.59 (m), 8.42-8.30 (m), 8.22 (d), 8.15 (d), 8.09 (d), 7.90-7.35 (m), 7.27 (d), 7.17 (d), 7.04 (d), 6.94 (d), 6.54 (d), 6.44 (s), 4.61 (d), 4.50-1.50 (m), 3.80 (s), 3.77 (s), 2.77 (s), 2.76 (s).

Example 45



15

N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl]-N-[(carboxamide)methyl]-3-cyano-1-naphthamide citrate.

N-[2-(S)-(3,4-Dichlorophenyl)-4-[4-(5-carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)-1-piperidinyl]butyl]-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide (0.351 g) was dissolved in 12 mL MeOH (2.0 M in NH_3) and heated to 80 °C in a sealed tube for 18 h. Mixture was cooled, MeOH was evaporated, product was purified by chromatography (100:1⇒20:1, DCM:MeOH w/0.5% conc. NH_3 (aq)) and converted to the citrate salt (0.148 g); MS: m/z 736 (M⁺); ¹H NMR ($\text{DMSO}-d_6$) δ 8.70-8.58 (m), 8.50-8.29 (m), 8.19-8.01 (m), 7.99-6.97 (m), 6.58-6.42 (m), 4.62-1.48 (m), 2.77 (s), 2.76 (s).

25

The intermediates were prepared as follows:

4-(2-Fluoro-4-methylthio-5-methoxycarbonylphenyl)-N-Cbz-piperidine.

To a mixture of DMSO (90 mL) and MeOH (90 mL) was added 1,3-bis(diphenylphosphino)propane (1.02 g), Pd(OAc)₂ (0.561 g), 4-(5-bromo-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine (5.18 g), and 2.5 mL Et₃N. Mixture was purged with
5 CO (via 18 ga. needle and balloon) for 30 minutes and heated to 70°C. Mixture was kept under CO atmosphere (atmospheric pressure) for 18 h at 70°C. At this time mixture was poured into 500 mL of 1:1 EtOAc:hexane, extracted with H₂O (6 x 150 mL), dried over MgSO₄, filtered, and concentrated. Residue was purified by chromatography (5:4.5:0.5, hexane:DCM:EtOAc) to give 1.38 g of product; MS m/z 418 (M⁺); ¹H NMR (CDCl₃) δ 7.89
10 (d), 7.45-7.25 (m), 6.92 (d), 5.16 (s), 4.50-4.21 (m), 3.90 (s), 2.99 (tt), 3.01-2.78 (m), 2.43 (s), 1.82 (dm), 1.79-1.51 (m).

4-(2-Fluoro-4-methylthio-5-carboxyphenyl)-N-Cbz-piperidine.

To a solution of 4-(2-fluoro-4-methylthio-5-methoxycarbonylphenyl)-N-Cbz-piperidine (1.38 g) dissolved in 100 mL 1:1 THF:H₂O was added 0.45 g LiOH. Mixture was stirred for 18 h,
15 THF was evaporated, residue was mixed with 25 mL 1N HCl, and extracted with DCM (3 x 50 mL). Extracts were combined, dried over Na₂SO₄, and evaporated to give 1.33 g product; MS m/z 404 (M+H); ¹H NMR (CDCl₃) δ 8.01 (d), 7.45-7.25 (m), 6.94 (d), 5.17 (s), 4.50-4.21 (m), 2.99 (tt), 3.01-2.78 (m), 2.44 (s), 1.84 (dm), 1.69 (qd).

4-(5-Carboxamide-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine.

20 To a solution of 4-(2-fluoro-4-methylthio-5-carboxyphenyl)-N-Cbz-piperidine (1.33 g) dissolved in 60 mL DCM was added 1.6 mL of N,N-diisopropylethylamine. Mixture was stirred for 10 min and then 1.15 g tetramethylfluoroformamidiniumhexafluorophosphate was added and stirring was continued for 1 h. At this point 1.05 g HOBt•NH₃ was added and the solution was stirred overnight. Then 20 mL of sat'd NaHCO₃ was added and the result was
25 extracted with DCM to give a solid (1.12 g) after purification by chromatography (20:1 DCM:MeOH); MS m/z 403 (M+H); ¹H NMR (CDCl₃) δ 7.57 (d), 7.48-7.27 (m), 6.99 (d), 6.46 (br s), 5.86 (br s), 5.15 (s), 4.51-4.21 (m), 2.99 (tt), 3.01-2.75 (m), 2.47 (s), 1.81 (dm), 1.68 (qd). HOBt•NH₃ was prepared using the procedure of Bajusz *et. al.* as described in *FEBS Letters*, 1977, 76, 91-92.

30 4-(5-Carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)-N-Cbz-piperidine.

To a stirred solution of NaIO₄ (4.30g) dissolved in 70 mL H₂O was added 4-(5-carboxamide-2-fluoro-4-methylthiophenyl)-N-Cbz-piperidine (1.12 g) dissolved in 70 mL THF. Mixture


- 56 -

was stirred at room temperature for 18 h, 50 mL sat'd NaHCO₃ was added and THF was evaporated. Result was extracted with DCM (3x75 mL). Organic extracts were combined, dried over Na₂SO₄, and evaporated to give 1.12 g of product after chromatography (20:1 DCM:MeOH); MS m/z 419 (M+H); ¹H NMR (CDCl₃) δ 7.98 (d), 7.52 (d), 7.43-7.25 (m), 6.39 (br s), 5.66 (br s), 5.15 (s), 4.50-4.22 (m), 3.14 (tt), 3.05-2.82 (m), 2.89 (s), 1.87 (dm), 1.80-1.52 (m).

4-(5-Carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)piperidine.

A solution of TFA (5 mL) and 4-(5-carboxamide-2-fluoro-4-(R,S)-methylsulfinylphenyl)-N-Cbz-piperidine (0.560 g) was heated to 90 °C for 0.5 h. TFA was evaporated, residue was mixed with 30 mL 20% KOH (aq), and extracted with CHCl₃. Extracts were combined, dried over Na₂SO₄, and evaporated. Residue was purified by chromatography (50:1⇒10:1, DCM:MeOH w/1% conc. NH₃ (aq)) to give 0.197 g product; MS m/z 285 (M+H); ¹H NMR (DMSO-d₆) δ 8.37 (br s), 7.95 (d), 7.75 (d), 7.68 (br s), 3.06 (d) 3.01-2.40 (m), 2.76 (s), 1.69 (br m).

Example 46




N-[2-(3,4-Dichlorophenyl)-4-(dimethylamino)butyl]-N-[(carboxamide)methyl]-1-naphthamide citrate.

Glycinamide hydrochloride (0.114 g) and 2-(3,4-dichlorophenyl)-4-(dimethylamino)-butanal (0.260 g) was stirred with 15 mL MeOH containing 0.15 mL Et₃N. When all had dissolved 0.30 mL HOAc was added and mixture was stirred for 1 h. At this time of NaCNBH₃ (0.100 g in 2 mL MeOH) was added and mixture was stirred for 18 h. At this point 30 mL of 20% K₂CO₃ (aq) was slowly added, MeOH was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na₂SO₄, filtered, and concentrated to afford N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-[(carboxamide)methyl]-amine which was used in the next step without purification; MS: m/z 318 (M+). 1-Naphthoyl chloride (0.202 g) was combined with N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-

[(carboxamide)methyl]-amine (0.318 g) and triethyl amine under standard acylation conditions to afford 0.253 g of product after purification by chromatography and conversion to the citrate salt; MS: m/z 472 (M^+); 1H NMR (DMSO- d_6) δ 8.30-8.20 (m), 8.00-6.85 (m), 4.56 (t), 4.42 (d), 4.20-1.90 (m), 1.80-1.45 (m).

5 **Example 47**




N-[2-(3,4-Dichlorophenyl)-4-(dimethylamino)butyl]-N-[2-aminoethyl]-1-naphthamide citrate.

A solution of TFA (3 mL) and N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-2-aminoethyl]-1-naphthamide (0.178 g) was stirred for 0.5 h. TFA was evaporated, residue was mixed with 30 mL 20% KOH (aq), and extracted with $CHCl_3$. Extracts were combined, dried over Na_2SO_4 , and evaporated. Product was converted to the citrate salt; MS: m/z 458 (M^+); 1H NMR (DMSO- d_6) δ 8.10-7.90 (m), 7.80-6.65 (m), 6.29 (d), 4.59 (t), 3.98-1.30 (m). From:

15 **N-[2-(3,4-Dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-2-aminoethyl]-1-naphthamide.**

Using standard reductive amination conditions 2-(3,4-dichlorophenyl)-4-(dimethylamino)-butanal (0.260 g) was reacted with *tert*-butyl N-(2-aminoethyl)-carbamate (0.166 g) to afford 0.404 g of product which was used in the next step without purification; MS: m/z 404 (M^+).

20 1-Naphthoyl chloride (0.191 g) was combined with N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-2-aminoethyl]-amine (0.404 g) and triethyl amine under standard acylation conditions to afford 0.178 g of N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-2-aminoethyl]-1-naphthamide after purification by chromatography (100:1 \Rightarrow 50:1, DCM:MeOH w/0.1% conc. NH_3 (aq)); MS: m/z 558 (M^+); 1H NMR ($CDCl_3$) δ 7.92-7.70 (m), 7.65-6.98 (m), 6.86 (d), 6.84-6.67 (m), 6.57 (d), 5.20 (br s), 4.40-2.50 (m), 2.21 (s), 2.03 (s), 2.00 (s), 1.48 (s), 1.41 (s), 2.40-1.20 (m).

Example 48

N-[2-(3,4-Dichlorophenyl)-4-(dimethylamino)butyl]-N-[3-aminopropyl]-1-naphthamide citrate.

- 5 A solution of TFA (3 mL) and N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-3-aminopropyl]-1-naphthamide (0.217 g) was stirred for 0.5 h. TFA was evaporated, residue was mixed with 30 mL 20% KOH (aq), and extracted with CHCl₃. Extracts were combined, dried over Na₂SO₄, and evaporated. Product was converted to the citrate salt; MS: m/z 472 (M⁺); ¹H NMR (DMSO-d₆) δ 8.10-7.90 (m), 7.80-7.00 (m), 6.95 (d), 6.75 (d), 6.58 (d), 6.27 (d), 4.59 (t), 3.89-1.31 (m).
- 10

From:

N-[2-(3,4-Dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-3-aminopropyl]-1-naphthamide.

- Using standard reductive amination conditions 2-(3,4-dichlorophenyl)-4-(dimethylamino)-butanal (0.260 g) was reacted with *tert*-butyl N-(3-aminopropyl)-carbamate (0.180 g) to afford 0.418 g of product which was used in the next step without purification; MS: m/z 418 (M⁺). 1-Naphthoyl chloride (0.191 g) was combined with N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-3-aminopropyl]-amine (0.418 g) and triethyl amine under standard acylation conditions to afford 0.217 g of N-[2-(3,4-dichlorophenyl)-4-(dimethylamino)butyl]-N-[N-boc-3-aminopropyl]-1-naphthamide after purification by chromatography (100:1⇒50:1, DCM:MeOH w/0.1% conc. NH₃ (aq)); MS: m/z 572 (M⁺); ¹H NMR (CDCl₃) δ 7.92-7.67 (m), 7.66-6.96 (m), 6.84 (d), 6.80-6.64 (m), 6.51 (d), 5.30 (br s), 4.39 (t), 4.21-2.40 (m), 2.21 (s), 2.04 (s), 1.99 (s), 1.45 (s), 1.34 (s), 2.35-1.20 (m).
- 15
- 20

The intermediates were prepared as follows:

- 25 **5-(*tert*-Butyldimethylsilyloxy)-4-(3,4-dichlorophenyl)-1-pentene.**

To a stirred solution of 4-[2-(3,4-dichlorophenyl)]-pentenol (23.93 g) in 500 mL DCM was added Et₃N (23.0 mL) and 4-dimethylaminopyridine (6.18 g). When all had dissolved *tert*-

butyldimethylsilyl chloride (22.90 g) was added, reaction was stirred for 3 h, quenched with 100 mL sat'd NaCO_3 , and DCM was evaporated. Aqueous mixture was extracted with EtOAc (3 x 120 mL). Organic extracts were combined and washed with 1N HCl (3 x 120 mL), sat'd NaHCO_3 (100 mL), and brine (100 mL). EtOAc layer was dried over MgSO_4 , filtered, and
5 concentrated to give an oil (31.34 g); ^1H NMR (CDCl_3) δ 7.37 (d), 7.33 (d), 7.06 (dd), 5.69 (ddt), 5.17-4.88 (m), 3.70 (d), 2.79 (tt), 2.57 (dt), 2.33 (dt), 0.87 (s), -0.03 (s).

5-(*tert*-Butyldimethylsilyloxy)-3-(3,4-dichlorophenyl)-1-butanol.

To a stirred slurry 5-(*tert*-butyldimethylsilyloxy)-4-(3,4-dichlorophenyl)-1-pentene (34.31 g) and NaIO_4 (46.01 g) in 900 mL 1:1 THF: H_2O was slowly added 30 mL OsO_4 solution (4%
10 w/w in H_2O). Mixture was stirred for 30 h, 200 mL sat'd $\text{Na}_2\text{S}_2\text{O}_3$ (aq) was added, mixture was stirred for 15 minutes, and filtered (cake was washed with THF (3 x 50 mL)). THF was evaporated, and aqueous residue was mixed with 500 mL 1:1 hexane:EtOAc. Organic layer was washed with sat'd $\text{Na}_2\text{S}_2\text{O}_3$ (aq) (150 mL), sat'd NaHCO_3 (200 mL), and brine (200 mL). Extract was dried over MgSO_4 , filtered, and concentrated. Product was purified by
15 chromatography (9:1, hexane:EtOAc) to give 16.4 g of an oil; ^1H NMR (CDCl_3) δ 9.76 (m), 7.39 (d), 7.36 (d), 7.09 (dd), 3.76 (dd), 3.63 (dd), 3.39 (dt), 2.96 (ddd), 2.73 (ddd), 0.88 (s), 0.02 (s).

N-[5-(*tert*-Butyldimethylsilyloxy)-3-(3,4-dichlorophenyl)butyl]-dimethylamine.

Dimethylamine hydrochloride (4.11 g) and 5-(*tert*-butyldimethylsilyloxy)-3-(3,4-
20 dichlorophenyl)-1-butanol (16.40 g) was stirred with 300 mL MeOH containing 7.80 mL Et_3N . When all had dissolved 14.5 mL HOAc was added and mixture (pH 4) was stirred for 1.5 h. At this time of NaCNBH_3 (4.94 g in 75 mL MeOH) was added via cannula and mixture was stirred for 3 h. At this point 200 mL of 20% K_2CO_3 (aq) was slowly added, MeOH was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na_2SO_4 ,
25 filtered, and concentrated to give an oil (17.75 g); MS: m/z 376 (M^+); ^1H NMR (CDCl_3) δ 7.38 (d), 7.34 (d), 7.08 (dd), 3.68 (d), 2.78 (dq), 2.24 (s), 2.32-2.10 (m), 2.09-1.95 (m), 1.73 (dtd), 0.87 (s), -0.02 (s), -0.03 (s).

2-(3,4-Dichlorophenyl)-4-(dimethylamino)-butanol.


To a stirred solution of N-[5-(*tert*-butyldimethylsilyloxy)-3-(3,4-dichlorophenyl)butyl]-
30 dimethylamine (17.75 g) in 100 mL THF was added tetrabutylammonium fluoride (70 mL of 1.0M in THF). Mixture was stirred for 3 h, THF was evaporated, residue was mixed with 150 mL 2 N KOH (with cooling), and extracted with CHCl_3 . Extracts were dried over Na_2SO_4 ,

filtered, and concentrated to give an oil which was purified by chromatography (50:1 \Rightarrow 10:1, DCM:MeOH w/1.0% conc. NH_3 (aq)) to afford 7.00 g product which was contaminated with tetrabutylammonium hydroxide; MS: m/z 262 (M⁺); ^1H NMR (CDCl_3) δ 7.36 (d), 7.31 (d), 7.06 (dd), 3.78-3.58 (m), 2.90-2.72 (m), 2.52 (ddd), 2.42-2.20 (m), 2.33 (s), 2.08-1.78 (m).

5 **2-(3,4-Dichlorophenyl)-4-(dimethylamino)-butanal.**

2-(3,4-Dichlorophenyl)-4-(dimethylamino)-butanol (1.40 g) was reacted with oxalyl chloride/DMSO under standard swern oxidizing conditions in DCM (80 mL) to afford (1.60 g crude) as a oil which was contaminated with tetrabutylammonium cation after aqueous extraction from DCM; MS: m/z 260 (M⁺); ^1H NMR (CDCl_3) δ 9.57 (d), 7.44 (d), 7.33 (d), 7.07 (dd), 3.66 (t), 2.35-2.03 (m), 2.22 (s).

Example 49



N-[2-(3,4-Dichlorophenyl)-4-dimethylamino]-N-[(carboxamide)methyl]-3-cyano-2-ethyl-1-naphthamide citrate.

15 **N-[2-(3,4-Dichlorophenyl)-4-(dimethylamino)]-N-[(carboxymethyl)methyl]-3-cyano-2-ethyl-1-naphthamide**

(0.276 g) was dissolved in 12 mL MeOH (2.0 M in NH_3) and heated to 80 °C in a sealed tube for 48 h. Mixture was cooled, MeOH was evaporated, product was purified by

chromatography (100:1 \Rightarrow 10:1, DCM:MeOH w/0.5% conc. NH_3 (aq)) and converted to the

20 **citrate salt (0.160 g); MS: m/z 525 (M⁺); ^1H NMR ($\text{DMSO}-d_6$) δ 11.07 (br m), 8.71-8.59 (m), 8.33 (d), 8.10 (d), 8.08-7.92 (m), 7.90-6.80 (m), 7.02 (s), 6.86 (s), 6.77 (d), 6.43 (d), 4.52 (t), 4.40-3.80 (m), 3.75-1.35 (m), 1.25-0.88 (m).**

The intermediates were prepared as follows:

N-[2-(3,4-Dichlorophenyl)-4-pentenylbutyl]-N-[(carboxymethyl)methyl]-3-cyano-2-ethyl-1-naphthamide.

3-Cyano-2-ethyl-1-naphthoyl chloride (0.49 g) was combined with N-[2-(3,4-dichlorophenyl)-4-pentenylbutyl]-N-[(carboxymethyl)methyl]-amine (0.57 g) and triethyl amine under

standard acylation conditions to afford N-[2-(3,4-dichlorophenyl)-4-pentenylbutyl]-N-[(carboxymethyl)methyl]-3-cyano-2-ethyl-1-naphthamide (0.51 g) as a solid after purification by chromatography (5:4:1 Hexane:DCM:EtOAc); MS: m/z 509 (M⁺); ¹H NMR (CDCl₃) δ 8.29 (s), 8.26 (s), 7.83 (d), 7.98-7.30 (m), 7.01 (d), 6.80 (s), 6.53 (d), 5.30-5.11 (m), 4.85-4.52 (m), 4.35-4.03 (m), 4.22 (s), 3.84 (s), 3.80 (s), 3.45 (dd), 3.32 (dd), 3.20-2.91 (m), 1.37 (t).

N-[2-(3,4-Dichlorophenyl)-4-oxobutyl]-N-[(carboxymethyl)methyl]-3-cyano-2-ethyl-1-naphthamide.


To a stirred slurry of N-[2-(3,4-dichlorophenyl)-4-pentenylbutyl]-N-[(carboxymethyl)methyl]-3-cyano-2-ethyl-1-naphthamide (0.51 g) and NaIO₄ (0.47 g) in 100 mL 1:1 THF:H₂O was slowly added 0.32 mL OsO₄ solution (4% w/w in H₂O). Mixture was stirred for 18 h, 10 mL sat'd Na₂S₂O₃ (aq) was added, THF was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na₂SO₄, filtered, and concentrated. This gave 0.64 g of N-[2-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(carboxymethyl)methyl]-3-cyano-1-naphthamide after purification by chromatography (100:1, DCM:MeOH); MS: m/z 511 (M⁺); ¹H NMR (CDCl₃) δ 9.53 (s), 8.25 (s), 7.79 (d), 7.70-7.20 (m), 6.89 (d), 6.73 (d), 6.48 (dd), 4.58-4.20 (m), 3.88 (s), 3.84 (s), 3.60-3.21 (m), 3.18-2.82 (m), 2.65-2.32 (m), 1.33 (t).

N-[2-(3,4-Dichlorophenyl)-4-(dimethylamino)]-N-[(carboxymethyl)methyl]-3-cyano-2-ethyl-1-naphthamide.

Dimethylamine hydrochloride (0.063 g) and N-[2-(3,4-dichlorophenyl)-4-oxobutyl]-N-[(carboxymethyl)methyl]-3-cyano-2-ethyl-1-naphthamide (0.380 g) was stirred with 10 mL MeOH containing 0.13 mL Et₃N. When all had dissolved 0.12 mL HOAc was added and mixture was stirred for 1.5 h. At this time of NaCNBH₃ (0.073 g in 2 mL MeOH) was added and mixture was stirred for 18 h. At this point 10 mL of 20% K₂CO₃ (aq) was slowly added, MeOH was evaporated, and aqueous residue was extracted with DCM. Extracts were dried over Na₂SO₄, filtered, and concentrated to give an oil (0.276 g) after chromatography (100:1⇒20:1, DCM:MeOH w/1.0% conc. NH₃ (aq)); MS: m/z 540 (M⁺); ¹H NMR (CDCl₃) δ 8.27 (s), 7.83 (d), 7.68-7.30 (m), 7.01 (d), 6.82 (d), 6.54 (dd), 4.35-4.12 (m), 3.84 (s), 3.82 (s), 3.50-3.28 (m), 3.19-2.93 (m), 2.80-2.65 (m), 2.01 (s), 1.78 (t), 1.36 (t).

Example 50


- 62 -



N-[(S)-2-(3,4-dichlorophenyl)-4-[4-[4-methoxy-(S*)-2-(methylsulfinyl)phenyl]-1-piperidinyl]butyl]-N-[2-oxo-2-dimethylaminoethyl]-3-cyano-2-methoxy-1-naphthamide citrate.

- 5 To a solution of N-[(S)-2-(3,4-dichlorophenyl)-4-[4-[4-methoxy-(S*)-2-(methylsulfinyl)phenyl]-1-piperidinyl]butyl]-N-[2-oxo-2-dimethylaminoethyl]-3-cyano-2-methoxy-1-naphthamide citrate, N,N-diisopropylethylamine, and dry DCM was added tetramethylfluoroformamidinium hexafluorophosphate (5 equiv.). After 5 min, dimethylamine (2M in THF) (150 equiv.) was then added. After stirring overnight, the mixture was concentrated, and the residue was
- 10 purified by flash chromatography. The purified free base (45 %) was converted to the citrate salt and isolated by filtration from Et₂O. MS APCI, m/z = 763 (M⁺) (free base); HPLC ^b 16.5.

Example 51



- N-[2-(S)-(3,4-dichlorophenyl)-4-hydroxybutyl]-N-[2-oxo-2-dimethylaminoethyl]-3-cyano-2-methoxy-1-naphthamide.**
- 15

N-[2-(S)-(3,4-dichlorophenyl)-4-(tert.-butyl-dimethylsilyloxy)-butyl]-3-cyano-2-methoxy-1-naphthamide^a and sodium hydride (1.3 equiv.) in dry DMF was stirred for 2 h, cooled (ice bath), then treated with N,N-dimethyl bromoacetamide (1.4 equiv.). Following deprotection (1M tetrabutylammonium fluoride in THF), the required product (85%) was obtained as a

20 mixture of atropisomers. MS APCI, m/z = 528 (M⁺). HPLC ^b 17.6.


^a Prepared from N-[2-(S)-(3,4-dichlorophenyl)-4-hydroxybutyl]-3-cyano-2-methoxy-1-naphthamide and tert. butyl dimethylsilyl chloride.

^b Analytical HPLC conditions employed were the following: Hewlett Packard HP1050 system using a Zorbax RX-C8, 4.6x250 mm, 5 micron column at 30 °C, with the following gradient:

5 0-0.5 min; 10% Solvent B, then ramping linearly to 100% Solvent B at 30 min at a fixed flow rate of 1.2 mL/min (Solvent A: 0.1% TFA in water; Solvent B: 0.1% TFA in acetonitrile); UV detection at 215 and 260 nm; retention time given in min.

CLAIMS:

1. A compound having the formula



5 wherein:

R^1 is C_{1-4} alkyl, substituted by 1 or 2 substituents selected from $-NR^aR^a$, $-NR^aC(=O)R^a$, $-C(=O)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-C(=O)OR^a$, $-S(=O)_nC_{1-6}$ alkyl, nitro, cyano and C_{1-3} haloalkyl; phenyl substituted by 0, 1, 2 or 3 substituents selected from $-NR^aR^a$, $-NR^aC(=O)R^a$, $-C(=O)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-C(=O)OR^a$, $-S(=O)_nC_{1-6}$ alkyl, nitro, cyano and C_{1-3} haloalkyl; or a 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms each independently selected from O, N and S and additionally having 0 or 1 oxo groups and 0 or 1 fused benzo rings;


R^2 is H, halogen, $-OR^9$ or C_{1-4} alkyl;

R^3 is H, halogen, $-OR^9$ or $-CN$;

15 R^4 is H, halogen, $-OR^9$ or C_{1-4} alkyl;

R^5 is H or CH_3 ;

R^6 is halogen, $-CH_2CO_2R^a$, $-CH_2C(=O)H$, $-CH_2CH=CH_2$, $-CH_2CH_2OR^a$, $-CH_2CH_2NR^aR^a$ or



20 R^7 is phenyl substituted by 0, 1, 2 or 3 substituents selected from C_{1-6} alkyl, $-NR^aR^a$, $-NR^aC(=O)R^a$, $-C(=O)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-C(=O)R^a$, $-C(=O)OR^a$, $-S(=O)_nC_{1-6}$ alkyl, nitro, cyano, C_{1-3} haloalkyl, trifluoromethylthio, trifluoromethylsulfinyl, C_{1-6} alkanesulfonamido, succinamido, carbamoyl, C_{1-6} alkylcarbamoyl, di- C_{1-6} alkylcarbamoyl,

C₁₋₆alkoxy-C₁₋₆alkylcarbamoyl, ureido, C₁₋₆alkylureido, di(C₁₋₆alkyl)ureido, bromo, fluoro, chloro and dimethylcarbamoylmethylureido; or

R⁷ is a 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms each independently selected from O, N and S and additionally having 0 or 1 oxo groups substituted
5 by 0 or 1 substituents selected from -OR^a, -OC(=O)R^a, -C(=O)OR^a, -C(=O)R^a, -NR^aR^a, -NR^aC(=O)R^a and -C(=O)NR^aR^a; or

R⁷ is hydrogen or NR^aR^a;

R⁸ is selected from hydrogen, -OR^a, -OC(=O)R^a, -C(=O)OR^a, -C(=O)R^a, -NR^aR^a, -NR^aC(=O)R^a, -C(=O)NR^aR^a, C₁₋₆alkyl, carbamoyl, C₁₋₆alkylcarbamoyl, and
10 bis(C₁₋₆alkyl)carbamoyl;

R^a is independently at each instance hydrogen or C₁₋₆alkyl;

R^b is C₁₋₆alkyl, phenyl or phenylC₁₋₆alkyl;


n is 0, 1 or 2; and

X¹ and X² are independently H, -CH₃ or halogen; or
15 any pharmaceutically-acceptable salt thereof.

2. A compound according to Claim 1, wherein X¹ and X² are H or halogen, and at least one of X¹ and X² are halogen.

20 3. A compound according to Claim 1, wherein R¹ is C₁₋₄alkyl, substituted by 1 or 2 substituents selected from -C(=O)NR^aR^a, -C(=O)OR^a and C₁₋₃haloalkyl; phenyl substituted by 0, 1, 2 or 3 substituents selected from -NR^aR^a, -NR^aC(=O)R^a, -OR^a, -OC(=O)R^a, nitro, cyano and C₁₋₃haloalkyl; or a 5- or 6-membered ring heterocycle containing 1, 2 or 3 nitrogen atoms.


25 4. A compound according to Claim 1, wherein R⁶ is



5. A compound according to Claim 1, wherein:

R^1 is C_{1-4} alkyl, substituted by 1 or 2 substituents selected from $-C(=O)NR^aR^a$, $-C(=O)OR^a$ and C_{1-3} haloalkyl; phenyl substituted by 0, 1, 2 or 3 substituents selected from $-NR^aR^a$, $-NR^aC(=O)R^a$, $-OR^a$, $-OC(=O)R^a$, nitro, cyano and C_{1-3} haloalkyl; or a 5- or 6-membered ring heterocycle containing 1, 2 or 3 nitrogen atoms; and

5 R^6 is



6. A compound according to Claim 5, wherein:

10 R^7 is phenyl substituted by 0, 1, 2 or 3 substituents selected from C_{1-6} alkyl, $-NR^aR^a$, $-NR^aC(=O)R^a$, $-C(=O)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-C(=O)R^a$, $-C(=O)OR^a$, $-S(=O)_nC_{1-6}$ alkyl, nitro, cyano, C_{1-3} haloalkyl, bromo, fluoro and chloro.

7. A compound according to Claim 5, wherein:

15 R^7 is a 5- or 6-membered ring heterocycle containing 1 or 2 heteroatoms each independently selected from O, N and S and additionally having 0 or 1 oxo groups substituted by 0 or 1 $-C(=O)NR^aR^a$.

8. A compound according to Claim 5, wherein R^7 is NR^aR^a .

20 9. A compound according to Claim 6, wherein R^8 is selected from hydrogen, $-NR^aR^a$, $-NR^aC(=O)R^a$ and $-C(=O)NR^aR^a$.

10. A compound according to Claim 7, wherein R^8 is selected from hydrogen, $-NR^aR^a$, $-NR^aC(=O)R^a$ and $-C(=O)NR^aR^a$.

25

11. A compound according to Claim 8, wherein R^8 is selected from hydrogen, $-NR^aR^a$, $-NR^aC(=O)R^a$ and $-C(=O)NR^aR^a$.

12. A method of treating major depressive disorder, severe anxiety disorders, stress
30 disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance

use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, emesis, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, COPD, hypertension, 5 migraine, bladder hypermotility, or urticaria comprising administering an effective amount of an NK1 antagonist according to any one of Claims 1 through 11.

13. A method for manufacturing a medicament comprising an effective amount of an NK1 antagonist according to any one of Claims 1 through 11 for the treatment of major depressive 10 disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, emesis, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, 15 Huntington's disease, COPD, hypertension, migraine, bladder hypermotility or urticaria.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 01/02858

A. CLASSIFICATION OF SUBJECT MATTER		
IPC7: C07D 211/24, C07C 255/57, C07D 417/12, C07D 211/22, C07D 211/34, C07D 211/20, A61K 31/445, A61K 31/44, A61P 25/00, A61P 29/00 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC7: C07C, C07D, A61K, A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0020003 A1 (ZENECA LIMITED), 13 April 2000 (13.04.00), page 1; page 2, figure 1a, claims 7,8 --	1-13
X	WO 0002859 A1 (ZENECA LIMITED), 20 January 2000 (20.01.00), figure 1, claim 13 --	1-13
X	WO 0069438 A1 (ASTRAZENECA AB), 23 November 2000 (23.11.00), Database CAPLUS, RN 263860-97-5, 263861-01-4, page 15 --	1-13
X	WO 0020389 A1 (ZENECA LIMITED), 13 April 2000 (13.04.00), Database CAPLUS, RN 263862-27-7, 263862-04-0, 263860-88-4, 263860-91-9, 263860-92-0 --	1-13
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
19 March 2002		25-03-2002
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Fernando Farieta/BS Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Internauonal application No.

PCT/SE 01/02858

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	The Journal of Pharmacology and Experimental Therapeutics, Volume 280, No 1, 1997, JuraJ Culman et al: "Effect of Tachykinin Receptor Inhibition in the Brain on Cardiovascular and Behavioral Responses to Stress", page 238 - page 246 --	1-13
A	US 5663179 A (BERNARD ANDRE DUMAITRE ET AL), 2 Sept 1997 (02.09.97), figure 1 -- -----	1-13

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/SE 01/02858

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0020003	A1	13/04/00	AU	4637899 A	01/02/00
				AU	6111099 A	26/04/00
				BR	9912013 A	10/04/01
				BR	9914333 A	26/06/01
				CN	1309638 T	22/08/01
				CN	1322134 T	14/11/01
				EP	1097137 A	09/05/01
				EP	1119355 A	01/08/01
				GB	9821703 D	00/00/00
				GB	9914886 D	00/00/00
				GB	9922519 D	00/00/00
				NO	20010151 A	05/03/01
				NO	20011766 A	05/06/01
				WO	0002859 A	20/01/00
				GB	9905238 D	00/00/00
WO	0002859	A1	20/01/00	AU	4637899 A	01/02/00
				BR	9912013 A	10/04/01
				CN	1309638 T	22/08/01
				EP	1097137 A	09/05/01
				GB	9814886 D	00/00/00
				GB	9914886 D	00/00/00
				NO	20010151 A	05/03/01
				AU	6111199 A	26/04/00
				BR	9915904 A	21/08/01
				CN	1322196 T	14/11/01
				EP	1119551 A	01/08/01
				GB	9821699 D	00/00/00
				GB	9922521 D	00/00/00
				NO	20011765 A	07/06/01
				WO	0020389 A	13/04/00
				AU	6111099 A	26/04/00
				BR	9914333 A	26/06/01
				CN	1322134 T	14/11/01
				EP	1119355 A	01/08/01
				GB	9821703 D	00/00/00
				GB	9922519 D	00/00/00
				NO	20011766 A	05/06/01
				WO	0020003 A	13/04/00
				GB	9909840 D	00/00/00
WO	0069438	A1	23/11/00	AU	4594200 A	05/12/00
				GB	9911017 D	00/00/00

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE 01/02858

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0020389	A1	13/04/00	AU	4637899 A	01/02/00
				AU	6111199 A	26/04/00
				BR	9912013 A	10/04/01
				BR	9915904 A	21/08/01
				CN	1309638 T	22/08/01
				CN	1322196 T	14/11/01
				EP	1097137 A	09/05/01
				EP	1119551 A	01/08/01
				GB	9821699 D	00/00/00
				GB	9914886 D	00/00/00
				GB	9922521 D	00/00/00
				NO	20010151 A	05/03/01
				NO	20011765 A	07/06/01
				WO	0002859 A	20/01/00
				GB	9906278 D	00/00/00
				GB	9909839 D	00/00/00
US	5663179	A	02/09/97	AU	4567193 A	31/01/94
				DE	69310367 D,T	14/08/97
				EP	0649410 A,B	26/04/95
				SE	0649410 T3	
				GR	3024073 T	31/10/97
				JP	8508974 T	24/09/96
				AT	152443 T	15/05/97
				DK	649410 T	15/09/97
				ES	2103479 T	16/09/97
				GB	9214667 D	00/00/00
				JP	2718830 B	25/02/98
				WO	9401408 A	20/01/94
				GB	9214668 D	00/00/00
				GB	9214675 D	00/00/00